RE:RE:RE:RE:Licensing agreement?With the bioavailability study completed CZO now has a destination. With a facility now licensed CZO has a place for scale-up. Since this intermediate level scale-up uses existing equipment and equipment CZO is already familar with and since yeast beta glucan and alginate are relatively easy to process I'm hoping this scale-up happens smoothly and relatively fast. With a facility that could produce 4 million doses of PGX-YBG, for instance, CZO could have its first commercial-scale facility. Having validated PGX through this intermediate scale-up step to commercial sales and with potential partners for formulation as the fibrosis trial also advances CZO could be in a very strong position for partnering. CZO could be a full strategic partner.
Ciao wrote: correction: the location of equipment for a "50L capacity" was mentioned in the June AGM, some equipment was said to originate from Boston and the German equipment bought over 2 years ago was still to be imported
Ciao wrote: I believe it was mentioned in one of the webcasts this year that the equipment is in Boston. Don't know when it arrived.
lscfa wrote: Where is the equipment purchased in Sept 2020 at? Had not yet been disassembled from German R&D facility in January 2021 (due to COVID?). I suspect the large jump in freight costs also has delayed shipment to Canada.